Experts in gesprek | Chronische Lymfatische Leukemie (CLL)

In dit programma gaan dr. Mark-David Levin en dr. Fransien de Boer in San Diego met elkaar in gesprek over het laatste ASH nieuws op het gebied van chronische lymfatische leukemie (CLL). Zij bespreken follow-up data van studies met targeted therapie in de eerste lijn, alsmede in de relapse setting en wat dit betekent voor de Nederlandse praktijk. Ook spreken zij over de ontwikkelingen van nieuwe behandelopties. 

Bekijk hier de andere delen van Experts in gesprek en de interviews van onze ASH coverage.

De volgende abstracts zijn ter sprake gekomen: 

Targeted therapie in de eerste lijn:

• First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study 
• Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study 
• First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial 

Tageted therapie in de relapse setting:

• Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study
• Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab

Nieuwe middelen:

• Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004
• Combination Treatment with  (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study